Analysts on Wall Street project that Idexx Laboratories (IDXX) will announce quarterly earnings of $2.68 per share in its forthcoming report, representing an increase of 5.1% year over year. Revenues are projected to reach $966.4 million, increasing 7.4% from the same quarter last year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Before a company an ...

Investors looking for stocks in the Medical - Instruments sector might want to consider either Thermo Fisher Scientific (TMO) or Idexx Laboratories (IDXX) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank i ...

In the latest market close, Idexx Laboratories (IDXX) reached $519.81, with a +0.99% movement compared to the previous day. The stock exceeded the S&P 500, which registered a gain of 0.15% for the day. Meanwhile, the Dow experienced a drop of 0.02%, and the technology-dominated Nasdaq saw an increase of 0.32%.Shares of the Animal diagnostic and health care company have depreciated by 6.13% over the course of the past month, underperforming the Medical sector's loss of 4.03% and the S&P 500's gain of 1.65%.T ...

Idexx Laboratories (IDXX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since a ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Idexx Laboratories (IDXX) , which belongs to the Zacks Medical - Instruments industry, could be a great candidate to consider.When looking at the last two reports, this Animal diagnostic and health care company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 8.09%, on average, in the last two quarters. ...

Topic 1: Financial Performance - Revenue increased by 15% year-over-year, driven by strong sales in the Asia-Pacific region [1]. - Net profit margin improved to 12%, up from 10% in the previous quarter [2]. - Operating expenses rose by 8%, primarily due to increased marketing and R&D investments [3]. Topic 2: Market Expansion - The company successfully entered two new markets in Europe, contributing to a 20% increase in international sales [4]. - A new distribution center was opened in South America to support regional growth [1]. - Strategic partnerships were formed with local retailers in Southeast Asia to enhance market penetration [3]. Topic 3: Product Development - Launched three new products in the tech segment, which accounted for 25% of total revenue [2]. - R&D investment increased by 10% to accelerate innovation and product differentiation [4]. - Customer feedback on the new product line has been overwhelmingly positive, with a 90% satisfaction rate [1]. Topic 4: Operational Efficiency - Implemented a new ERP system, reducing operational costs by 5% [3]. - Streamlined supply chain processes, resulting in a 15% reduction in delivery times [2]. - Employee training programs were expanded, leading to a 10% increase in productivity [4]. Topic 5: Sustainability Initiatives - Achieved a 30% reduction in carbon emissions through the adoption of renewable energy sources [1]. - Launched a recycling program that has successfully recycled 50% of manufacturing waste [3]. - Committed to achieving net-zero emissions by 2030, with interim targets set for 2025 [2]. Topic 6: Corporate Governance - Appointed two new independent directors to the board, enhancing governance and oversight [4]. - Implemented a new whistleblower policy to ensure ethical practices across the organization [1]. - Conducted annual audits, resulting in a 100% compliance rate with regulatory requirements [3].

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 29, 10:50 am – 11:30 am EST – Brian McKeon, Executive Vice President and Chief Financial Officer, and Tina Hunt, PhD, Executive Vice President, Strategy, Sector Development and Global Operations, will participate in a fireside chat at the BofA Securities Animal Health Virtual Summit. Monday, March 4, 11:00 am – 11:30 am ...

IDEXX Laboratories, Inc. (IDXX) is likely to grow in the coming quarters, backed by the sustained success of CAG’s recurring diagnostic products and services. The company’s international business performance is gaining from its expanded global commercial capability. However, IDEXX’s operations are prone to macroeconomic challenges and foreign exchange fluctuations.In the past year, this Zacks Rank #3 (Hold) stock has increased 8.9% compared with the 3.7% rise of the industry and 22.1% growth of the S&P 500 ...

IDEXX Laboratories, Inc.’s (IDXX) strong global expansion and improved commercial capability aid growth. However, macroeconomic woes dent growth. The stock carries a Zacks Rank #3 (Hold).IDEXX’s Diagnostics business is one of the fastest-growing areas in the veterinary clinic space since the determination of a patient's health status and the best treatment path often require testing. IDEXX provides advanced diagnostic capabilities that meet veterinarians’ diverse needs through a variety of modalities, inclu ...

Financial Data and Key Metrics - Q4 2023 revenue increased 8% organically, driven by 10% organic growth in CAG Diagnostic recurring revenues [7] - Q4 operating profit increased 8% as reported and 10% on a comparable basis, with EPS of $2.32, up 17% on a comparable basis [8] - Full-year 2023 organic revenue growth was 9%, with EPS increasing 29% on a comparable basis [9] - Full-year CAG Diagnostic recurring revenues grew 10.5% organically, with 11% growth in the US and 10% internationally [10] - Free cash flow for 2023 was $773 million, representing 91% of net income [33] Business Line Performance - CAG Diagnostic recurring revenue grew 10% organically in Q4, with 9% growth in the US and 12% internationally [13] - VetLab consumable revenues increased 13% organically in Q4, supported by an 11% increase in the global premium install base [18] - Rapid Assay revenue grew 9% organically in Q4, while CAG instrument revenues declined 3% organically [20] - Veterinary Software and Diagnostic Imaging revenues increased 6% organically in Q4, with 19% organic growth in recurring revenues for the full year [21] - Water revenues grew 5% organically in Q4, while Livestock, Poultry, and Dairy (LPD) revenues declined 4% organically [22][23] Market Performance - US CAG Diagnostic recurring revenue grew 9% organically in Q4, with a 1,050 basis point growth premium compared to US clinical visit growth levels [15][16] - International CAG Diagnostic recurring revenue grew 12% in Q4, supported by strong premium instrument placements [17] - Severe US weather in January 2024 is expected to impact Q1 clinical visit growth by approximately 1% [39][48] Strategy and Industry Competition - The company is targeting 10% organic revenue growth for 2024, supported by 7.5% to 10.5% growth in CAG Diagnostic recurring revenues [12][36] - IDEXX is advancing its growth strategy through innovation, including the launch of the IDEXX inVue Dx Analyzer in Q4 2024 [79][80] - The company is expanding its global commercial capabilities, with recent US and international expansions [64][65] - IDEXX is focusing on cloud-based software solutions, with over 90% of PIMS placements being cloud-native in Q4 2023 [70] Management Commentary on Operating Environment and Future Outlook - Management highlighted strong execution in 2023, with double-digit growth in CAG Diagnostics recurring revenues and high customer retention rates [53][54] - The company expects flat US clinical visit growth post-Q1 2024, with potential upside from sector improvement [95][97] - IDEXX is well-positioned to address long-term growth opportunities in companion animal healthcare through innovation and commercial partnerships [56][124] Other Important Information - The company repurchased 90,000 shares in Q4 2023 and 175,000 shares for the full year [35] - IDEXX expects a 1.5% increase in its effective tax rate to approximately 22% in 2024 [46] - The company recently acquired a US-based software and data platform to enhance its software ecosystem [76] Q&A Summary Question: Revenue Guidance Range for 2024 - The wider revenue guidance range for 2024 reflects potential sector improvement and macroeconomic risks, with the midpoint assuming flat US clinical visit growth [94][95] Question: Clinical Visit Expectations and Volume Growth - Q1 2024 clinical visit growth is expected to be impacted by severe US weather, with flat growth expected post-Q1 [97][122] - Q4 2023 saw the strongest normalized volume growth of 4% in both US and international markets, driven by strong execution [90][97] Question: IDEXX inVue Dx Analyzer Launch - The inVue Dx Analyzer is expected to launch in Q4 2024, with initial focus on ear cytology and blood morphology tests [102][105] - Customer feedback on the inVue Dx Analyzer has been positive, particularly for its ability to eliminate slide preparation [110] Question: Pricing and Competitive Landscape - IDEXX expects 5% net price gains globally in 2024, consistent with historical levels and customer value perception [102][106] - The competitive landscape remains dynamic, with IDEXX focusing on innovation and integrated solutions to maintain its position [115] Question: Gross Margin and Operating Expense Outlook - IDEXX expects 20 to 70 basis points of comparable operating margin improvement in 2024, driven by gross margin gains and continued investment in innovation [120] - Operating expenses are expected to grow in line with revenue, with a focus on commercial and R&D investments [120]